Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66.6M
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
18.7M
-
Shares change
-
+13.8M
-
Total reported value, excl. options
-
$265M
-
Value change
-
+$208M
-
Put/Call ratio
-
0.45
-
Number of buys
-
52
-
Number of sells
-
-10
-
Price
-
$14.19
Significant Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q3 2020
76 filings reported holding CRDF - Cardiff Oncology, Inc. - Common Stock as of Q3 2020.
Cardiff Oncology, Inc. - Common Stock (CRDF) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.7M shares
of 66.6M outstanding shares and own 28.1% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (3.29M shares), CAXTON CORP (1.85M shares), Opaleye Management Inc. (1.73M shares), VR Adviser, LLC (1.27M shares), VANGUARD GROUP INC (1.03M shares), JANUS HENDERSON GROUP PLC (1.01M shares), FMR LLC (979K shares), Corriente Advisors, LLC (910K shares), Artal Group S.A. (900K shares), and PRICE T ROWE ASSOCIATES INC /MD/ (553K shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.